Stay updated on Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy evaluation of two immunotherapy regimens in patients with advanced melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:23:00.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    52%
    Check dated 2024-05-22T20:28:43.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:35:14.000Z thumbnail image

Stay in the know with updates to Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.